Get the Stockscreener App
12.88
1.45%
-0.19
Pre-market:
13.08
0.20
+1.55%
Ultragenyx Pharmaceutical Inc stock is traded at $12.88, with a volume of 5.01M.
It is down -1.45% in the last 24 hours and down -51.38% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
See More
Previous Close:
$13.07
Open:
$13.07
24h Volume:
5.01M
Relative Volume:
1.64
Market Cap:
$1.27B
Revenue:
$669.43M
Net Income/Loss:
$-609.36M
P/E Ratio:
-2.1094
EPS:
-6.1061
Net Cash Flow:
$-507.20M
1W Performance:
-9.99%
1M Performance:
-51.38%
6M Performance:
-40.97%
1Y Performance:
-56.31%
1-Day Range:
$12.73
$13.22
1-Week Range:
$12.73
$14.70
52-Week Range:
$12.73
$39.89
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
12.88 | 1.41B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
513.26 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
774.61 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.69 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.62 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
195.92 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Downgrade | Goldman | Buy → Neutral |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | William Blair | Outperform |
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Why Did RARE Stock Slump 46% After-Hours? - Stocktwits
Technical Reactions to RARE Trends in Macro Strategies - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire about Securities Investigation - ACCESS Newswire
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Squarepoint Ops LLC Sells 106,171 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx’s GTX-102 failure erases pipeline sales expectations - spglobal.com
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout - Stocktwits
Ultragenyx SVP Theodore Huizenga sells $2,252 in shares By Investing.com - Investing.com South Africa
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Ultragenyx SVP Theodore Huizenga sells $2,252 in shares - Investing.com
Ultragenyx (NASDAQ: RARE) exec sells 161 shares for RSU tax, keeps 69,146 - Stock Titan
$Ultragenyx Pharmaceutical (RARE.US)$ get ready - moomoo.com
Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Angelman Trial Failure And Cost-Cut Plan - Yahoo Finance
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Ultragenyx (RARE) Stock Looks Fully Valued Following Its Phase 3 Setback - Yahoo Finance
Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose - Reuters
RARE Stock Plunges As Ultragenyx Misses Key GTX-102 Trial - StocksToTrade
Ultragenyx Stock Crashes After GTX-102 Failure Despite Genglycos Win - timothysykes.com
Ultragenyx Stock Crashes As GTX-102 Failure Erases Optimism - StocksToTrade
RARE Stock Crashes As Ultragenyx Faces GTX-102 Trial Failure - timothysykes.com
The Goldman Sachs Group Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
This week in charts: China deals, stock flatlines and Lilly’s M&A spree - BioPharma Dive
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap UpTime to Buy? - MarketBeat
Rx Rundown: Eli Lilly, Ultragenyx, Novartis and more - Medical Marketing and Media
Barclays Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharma Is Maintained at Overweight by Barclays - moomoo.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to "Hold" at Royal Bank Of Canada - MarketBeat
Wellington Management Group LLP Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx: A 44% Crash After Trial Failure, Two Weeks After First Gene Therapy Approval - Kavout
Ultragenyx Pharmaceutical (RARE) Reports 61% Cornstarch Reduction In 96 Week Phase 3 Data - simplywall.st
Ultragenyx vows 'significant' cuts after experimental rare-disease drug flunks late-stage clinical trial - The Business Journals
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $28.00 by Analysts at Jefferies Financial Group - MarketBeat
Ultragenyx Pharma Cut to Market Perform From Outperform by William Blair - Moomoo
Ultragenyx: Angelman Study Setback Creates More Risk For Rare Disease Specialist - Seeking Alpha
Ultragenyx's Apazunersen Fails Phase III Trial | PharmExec - Pharmaceutical Executive
Ultragenyx Shares Crater After Angelman Syndrome Drug Fails Pivotal Trial - finance.biggo.com
Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder - MedCity News
Ultragenyx Pharmaceutical Target of Unusually Large Options Trading (NASDAQ:RARE) - MarketBeat
Ultragenyx Weighs Future of Angelman Syndrome ASO After Phase III Trial Failure - GenomeWeb
Citigroup Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline - Barron's
QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target - Benzinga
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $18.00 Price Target at TD Cowen - MarketBeat
Angelman wings clipped by Ultragenyx phase III bust - BioWorld News
Ultragenyx's Apazunersen Fails Phase 3 Angelman Syndrome Trial - BioPharm International
Ultragenyx mulls fate of rare disease programme on Phase III flop - Clinical Trials Arena
Ultragenyx stock downgraded after trial setback (RARE:NASDAQ) - Seeking Alpha
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report? - Yahoo Finance
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals - TradingView
Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study - BioPharma Dive
Ultragenyx sinks as Phase 3 Angelman trial miss slams a key pipeline bet - Quiver Quantitative
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ultragenyx Pharmaceutical Inc Stock (RARE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Parschauer Karah Herdman | EVP and Chief Legal Officer |
Aug 03 '26 |
Sale |
24.92 |
1,900 |
47,348 |
92,562 |
| Horn Howard | Chief Financial Officer |
Aug 03 '26 |
Sale |
24.92 |
4,696 |
117,024 |
96,295 |
0.00%
4.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):